EP0255824B1 - A process for the production of refined fish oil concentrate - Google Patents
A process for the production of refined fish oil concentrate Download PDFInfo
- Publication number
- EP0255824B1 EP0255824B1 EP86906964A EP86906964A EP0255824B1 EP 0255824 B1 EP0255824 B1 EP 0255824B1 EP 86906964 A EP86906964 A EP 86906964A EP 86906964 A EP86906964 A EP 86906964A EP 0255824 B1 EP0255824 B1 EP 0255824B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fatty acid
- concentrate
- urea
- cholesterol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
Definitions
- the present invention concerns a process for producing refined fish oil concentrate.
- cholesterol and useful by products such as urea adducts of fatty acid compounds are produced, in addition to higher unsaturated fatty acids.
- waste products from the fish refining industry contain usable products, among others fatty acids, cholesterol, proteins and enzymes. These are either fat-soluble or water-soluble. Such waste products are normally referred to as fish entrails.
- the water-soluble portion containing proteins and enzymes may be separated from the fat-soluble portion.
- the present invention concerns the fat-soluble portion of the waste products, but it can also use other refined fish oils such as occur for instance in the fish product industry. In the following these basic raw materials will be called «fish oil product”.
- fatty acids the following may be specified as suitable for the medicinal purposes referred to : eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Both fatty acids are w 3-fatty acids of the C-20 and C-22 acids..Their nomenclature according to the IUPAC system is:
- docosahexaenoic acid 22 6 ⁇ 3
- 20 and 22 indicate the number of C-atoms respectively in the molecule of the fatty acid, 5 and 6 the number of unsaturated bondings, and ⁇ 3 that the last unsaturated bonding is positioned at a distance of 3 carbon atoms from the w-position.
- the fat soluble portion of cod entrails usually contains 10-25 % of the fatty acid compounds EPA and DHA, sometimes referred to herein as the essential fatty acid compounds, as well as 2-4 % cholesterol.
- the remainder is mainly fatty acid compounds with lower unsaturation, such as pure fatty acids or their glycerides.
- the purpose of the invention is to treat fish oil product so as to separate the fatty acid compounds EPA and DHA from cholesterol and other fatty acid compounds, and thereby from a concentrate containing high concentrations of EPA and DHA.
- esters for instance as methyl or ethyl esters.
- trans-esterification and esterification for instance with methanol for production of fatty acid methyl esters.
- This basic material is well suited for further separation of EPA and DHA and cholesterol from the remaining less important fatty acid compounds.
- Another patent, SU-A-950,393 describes a method for production of cholesterol from, for instance, fish waste products by hydrolysing the fatty acid compounds and converting them to soaps. These are then subjected to an extraction of trichlorethylene at room temperature, whereby the cholesterol is combined with the trichlorethylene and this compound is then subject to further separation.
- GB-A-1,240 513 also concerns a separation technique by means of urea where the raw material consists of pure methyl and ethyl esters of the C 16 -C 18 fatty acids. Urea precipitation occurs in a neutral environment with a surplus of the relevant alcohol. The purpose is to be able to obtain a stronger concentration of y-linolenic acid.
- the above-mentioned fatty acid esters do not contain any higher fatty acids other than C-18 in the form of stearic acid, oleic acid, linoleic acid and linolenic acid, which after the urea precipitation and separation of the urea adduct from the rest of the material has obtained a higher content of y-linolenic acid by means of chromotography.
- the higher unsaturated fatty acid compounds 20 : 5 w3 and 22 : 6 w3 may be concentrated according to a method described in Japanese Patent Publication No. 59-071396 where the fatty acid compounds mentioned are extracted by means of polar solvents, such as acetone, methyl ethyl ketone, methanol, ethanol, and similar solvents, whereby a soluble and an insoluble extract are formed. Thereafter the extract is further processed to obtain essential fatty acid compounds.
- polar solvents such as acetone, methyl ethyl ketone, methanol, ethanol, and similar solvents
- the present invention provides a process for the production of a refined fish oil concentrate containing at least 20 % eicosapentaenoic acid (EPA) and at least 35 % docosehexaensoic (DHA) by weight, the remainder of the concentrate including other unsaturated fatty acid compounds, and the fatty acid compounds of the concentrate being mainly present as alkyl esters of lower alcohols, which comprises the steps of :
- a one special feature of this process is that fatty acid compounds are not separated prior to precipitation of the urea adduct, but instead precipitate from the same non-uniform mixture of components like they are found in the basic raw material.
- Another special feature is that the precipitation of the urea adduct takes place in an alkaline environment, and in such a way that the alkaline environment is created through applying the base only in catalytic quantities such as a catalytic agent for the trans-esterification of glycerides to methyl esters and not as a means of saponification of the fatty acids.
- a third special feature is that the esterification and/or trans-esterification takes place at room temperature.
- a result of esterification or trans-esterification at low temperature and in an environment with low alkalinity is that isomerization of the double bonds is avoided, which results in a more uniform product with no toxic effect. At the same time transconfigurations are avoided.
- the remaining solution is thereafter extracted by means of a non-polar solvent, for example hexane, whereby the w3-fatty acids as well as cholesterol will be found in the non-polar phase.
- the non-polar phase is treated to remove the solvent, as by being subjected to evaporation of the solvent under moderate conditions, for instance by means of vacuum distillation.
- the remaining ⁇ 3-concentrate now contains all the cholesterol, and it becomes apparent that the cholesterol does not dissolve easily in this concentrate and will crystallize on cooling.
- the M 3- concentrate which is left will contain 20-30 per cent EPA by weight and 35-50 % DHA by weight.
- the remainder of the concentrate consists mainly of non-essential fatty acid compounds which are not important for our purpose.
- FIG. 1 shows diagrammatically one way of carrying out the invention and where each block represents a step in the process and is marked with a reference number.
- the flow. of the material to and from each block and between the blocks is marked by solid and dotted lines.
- each material is characterized by a letter.
- the basic material is fat and/or fatty acids from fish and especially fat and/or fatty acids obtained from the fish processing industry in connection with ensilage and or auto-catalysis processes, but the process may also be used with other forms of marine fat.
- This fatty raw material is called fish oil product in the claims.
- Such fat/fatty acids have a high content of saturated, unsaturated and polyunsaturated fatty acids with a chain length C 18, C 20 and C 22 as well as a certain amount of cholesterol, vitamins and other fat soluble products which are undefin- able, usually characterized as unsaponifiable, as well as fatty acid compounds with shorter chain lengths.
- B alcohol with a low boiling point
- methanol or ethanol for instance methanol, preferably methanol
- C auxiliary compounds
- Potassium hydroxide may be used as a catalytic agent, and in order to prevent oxidization, especially when heavy metals such as chromium, iron, cobalt, nickel and copper are present, small amounts of the sodium salt of ethylenediaminetetra-acetic acid (EDTA-Na 3 ) may be added.
- EDTA-Na 3 ethylenediaminetetra-acetic acid
- the esterification and trans-esterification take place under moderate conditions and stirring at about 20 °C for some hours.
- the formation of alkyl esters is nearly complete when the ester product has changed its appearance from opalescent to clear.
- the clear solution (D1) therefore contains alkyl esters of the fatty acids, glycerol, alkanol, as well as some water from the esterification of the free fatty acids.
- the clear solution is then heated to a temperature of 55-90°, preferably 60-80°, most preferably 65-68 °C, whereafter a fixed amount of urea (E) and alkanol (B) is added and stirred in until everything is completely dissolved.
- the amount of urea depends on the composition of the fatty acids so that if the raw material (A) contains 6-8 % EPA by weight, urea is added in the ratio 3 parts urea by weight to 1 part alkyl ester. In order to ensure that the components are completely soluble, 9 parts alkanol by weight is added.
- the slightly alkaline filter mass (G) is saturated with hexane or other non-polar solvent, preferably hexane, and is extracted by means of this solvent through a known technique, as, for instance, by a continuing fluid-to-fluid counter current process, whereafter a further quantity of adduct of urea fatty ester may be crystallized.
- hexane I
- K residue
- the hexane extract (1) which contains the alkyl- fatty esters of the polyunsaturated fatty acids 18 : 4003,20: 5 ⁇ 3-and22 : 6 00 3 as well as cholesterol as the most important components, is washed in dilute hydrochloric acid (L) in order to neutralize possible potassium soaps of the essential polyunsaturated fatty acids in the hexane extract.
- the washing water is decanted.
- Hexane (H) is thereafter removed by evaporation of the extract (1) so that a concentrate is produced which is free from solvents (N) and which contains the compounds that are essential for the invention, the fatty acid compounds EPA and DHA as well as cholesterol.
- the dehydrated extract normally contains 20-30 % EPA, 35-45 % DHA, 10-20 % other polyunsaturated fatty acids, as well as 5-15 % cholesterol and undefined compounds, all by weight, but the exact composition referred to will depend on the type of fish used, the time of year the fish is caught, and the type and condition of the raw material.
- alkyl fatty acid ester (N) is thereafter cooled to approx. minus 25 °C, whereafter cholesterol (O) is crystallized. This is centrifuged and/or filtered.
- w3-concentrate (P) thus contains 20-35% EPA, 35-50 % DHA and 15-25 % of other polyunsaturated w3-fatty acid compounds (all by weight) as well as unsaturated fatty acid compounds which are not essential for the invention.
- Product .(p) which contains the alkyl esters of the corresponding w3-fatty acids may be utilized as it is or if desired the concentration of EPA and DHA may be increased.
- the product contains only small amounts of other fatty acids with the same chain length as EPA and DHA, it is well suited for separation of the essential fatty acids, EPA and DHA, by means of supercritical fluid extraction.
- Another method for increasing the concentration is by means of preparative liquid chromatography by which method a more than 90 % purity of the essential fatty acids is obtained.
- a hexane fraction (R) is precipitated in an upper layer which is separated.
- the hexane fractions (R) contain free fatty acids as well as some of their alkyl esters and fairly high percentages of EPA and DHA, but also a fairly substantial portion of C 18-, C 20- and C 22-fatty acids with lower unsaturation.
- This acid solution contains water, alcohol, alkanol, glycerol, urea and other products which may be retrieved by a separate process which is not described here.
- the fatty acid components of the hexane fraction are increased by evaporating hexane (H) in a separate piece of equipment.
- the remaining solution is esterified using lower alkanols, for instance methanol or ethanol by means of an appropriate catalytic agent (V) which for instance may be dehydrated hydrochloric acid, acetic acid chloride or boron-trichloride.
- V catalytic agent
- the resultant alkyl ester (D2) from the fatty acid components (T) from box 7 may be processed in various ways, for instance returned to box 2 for urea precipitation of the less unsaturated fatty acids.
- the whole mixture was subjected to stirring for 15 hours at 20 °C in order to bring about a trans-esterification of the glycerides to methyl esters and esterification of the free fatty acids to methyl esters.
- the urea adduct was separated from the solution by decanting and filtering according to an ordinary, known technique. Result : 100.1 kg urea adduct (F).
- This filtrate (G) contained 003-polyunsaturated fatty acid methyl esters, cholesterol and a residue of unwanted fatty acid fractions with lower unsaturated C 18, C 20 and C 22 fatty acid methyl esters.
- To this filtrate we added hexane for saturation, whereby a further amount of urea adduct (22 kg) could be separated.
- This hexane-saturated solution was extracted in a counter-current with hexane so that the hexane extract (1) finally made up approx. 300 I. The remaining unextracted solution is called (K). The hexane extract was thereafter evaporated.
- the yield of 003-fatty acid methyl ester concentrate 10.2 kilos.
- the concentrate (N) which contained 23 % EPA, 41 % DHA and 8 % cholesterol, all by weight, was thereafter cooled to minus 25 °C, whereby pure cholesterol (O) crystallized and was removed by means of centrifuging during which time the residue in the centrifuge was washed with hexane with a lower temperature in order to remove the fatty acid methyl esters from the cholesterol crystals. Yield : 760 g pure cholesterol.
- the concentrated filtrate (P) contained 25 % EPA-methy. lester, 43 % DHA-methylester by weight based on the fatty acid portion, and traces of cholesterol.
- Another advantage with the invention is that it is possible to produce a urea adduct without following the cumbersome procedure of first producing the fatty acids, esterify these with alkanol and then separating them by means of the fractionated urea precipitation.
Abstract
Description
- The present invention concerns a process for producing refined fish oil concentrate. In the refining process, cholesterol and useful by products such as urea adducts of fatty acid compounds are produced, in addition to higher unsaturated fatty acids.
- It is known that waste products from the fish refining industry contain usable products, among others fatty acids, cholesterol, proteins and enzymes. These are either fat-soluble or water-soluble. Such waste products are normally referred to as fish entrails.
- Through the processing of fish entrails, the water-soluble portion containing proteins and enzymes may be separated from the fat-soluble portion. The present invention concerns the fat-soluble portion of the waste products, but it can also use other refined fish oils such as occur for instance in the fish product industry. In the following these basic raw materials will be called «fish oil product".
- It is known that certain essential fatty acids in fish oil have a medicinal effect and are useful in the prevention and cure of thrombotic illnesses, for instance ischemic heart disease. In addition, these compounds lower the cholesterol level in the blood.
- Among the above-mentioned fatty acids, the following may be specified as suitable for the medicinal purposes referred to : eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Both fatty acids are w 3-fatty acids of the C-20 and C-22 acids..Their nomenclature according to the IUPAC system is:
- for the eicosapentaensoic acid (EPA) :
- cis - 5, 8, 11, 14, 17 - eicosapentaenoic acid ; and for the docosahexaenoic acid (DHA) :
- cis - 4, 7, 10, 13, 16, 19 - docosahexaenoic acid ;
- which are sometimes abbreviated to:
- eicosapentaenoic acid 20 : 5 ω3, and
- docosahexaenoic acid 22 : 6 ω3 where 20 and 22 indicate the number of C-atoms respectively in the molecule of the fatty acid, 5 and 6 the number of unsaturated bondings, and ω3 that the last unsaturated bonding is positioned at a distance of 3 carbon atoms from the w-position.
- In the following we will be using the designations EPA and 20 : 5 ω3 for the eicosapentaenoic acid and DHA and 22:6 ω3 for the docosahexaenoic acid.
- The fat soluble portion of cod entrails, for instance, usually contains 10-25 % of the fatty acid compounds EPA and DHA, sometimes referred to herein as the essential fatty acid compounds, as well as 2-4 % cholesterol. The remainder is mainly fatty acid compounds with lower unsaturation, such as pure fatty acids or their glycerides.
- The purpose of the invention is to treat fish oil product so as to separate the fatty acid compounds EPA and DHA from cholesterol and other fatty acid compounds, and thereby from a concentrate containing high concentrations of EPA and DHA.
- It has long been known that the easiest way to separate fatty acids is by means of extraction or distillation when they appear in the form of esters, for instance as methyl or ethyl esters. Before treatment, fatty waste products from the fish industry must have been subjected to trans-esterification and esterification, for instance with methanol for production of fatty acid methyl esters.
- This basic material is well suited for further separation of EPA and DHA and cholesterol from the remaining less important fatty acid compounds.
- In US-A-4,145,446 a method is described for precipitation of fatty acid compounds in raw material by means of urea. The purpose is to obtain a product containing proteins and fats, suitable for fodder. The production of the urea adduct is brought about by providing a solution of melted urea at 60-140 °C to which is added melted fatty acid or a mixture of fats heated to a temperature of 35-105° so that the ratio fat/fatty acids to urea will be from 40/60 to 60/40 units by weight.
- Another patent, SU-A-950,393 describes a method for production of cholesterol from, for instance, fish waste products by hydrolysing the fatty acid compounds and converting them to soaps. These are then subjected to an extraction of trichlorethylene at room temperature, whereby the cholesterol is combined with the trichlorethylene and this compound is then subject to further separation.
- GB-A-1,240 513 also concerns a separation technique by means of urea where the raw material consists of pure methyl and ethyl esters of the C16-C18 fatty acids. Urea precipitation occurs in a neutral environment with a surplus of the relevant alcohol. The purpose is to be able to obtain a stronger concentration of y-linolenic acid. The above-mentioned fatty acid esters do not contain any higher fatty acids other than C-18 in the form of stearic acid, oleic acid, linoleic acid and linolenic acid, which after the urea precipitation and separation of the urea adduct from the rest of the material has obtained a higher content of y-linolenic acid by means of chromotography.
- The higher unsaturated fatty acid compounds 20 : 5 w3 and 22 : 6 w3 may be concentrated according to a method described in Japanese Patent Publication No. 59-071396 where the fatty acid compounds mentioned are extracted by means of polar solvents, such as acetone, methyl ethyl ketone, methanol, ethanol, and similar solvents, whereby a soluble and an insoluble extract are formed. Thereafter the extract is further processed to obtain essential fatty acid compounds.
- According to the present invention it is now possible - in a remarkably simple manner - to optimize the procedure to increase the concentration of 003-fatty acid compounds and cholesterol. This is based on a fractionated precipitation of the less interesting fatty acid compounds with urea, since urea tends to form an adduct with fatty acids which do not belong to the m3 type, wherens fatty acids of m3 type do not. Nor does cholesterol form an adduct with urea. The procedure used previously was to isolate the fatty acid compounds before these were esterified separately, and then they were subjected to a fractionated precipitation with urea. This procedure is unnecessary with our invention.
- Thus, the present invention provides a process for the production of a refined fish oil concentrate containing at least 20 % eicosapentaenoic acid (EPA) and at least 35 % docosehexaensoic (DHA) by weight, the remainder of the concentrate including other unsaturated fatty acid compounds, and the fatty acid compounds of the concentrate being mainly present as alkyl esters of lower alcohols, which comprises the steps of :
- (a) esterifying and/or trans-esterifying the fat/fatty acid fraction of fish oil product at room temperature with a lower alcohol in an alkaline environment containing amounts of base sufficient only to catalyze the esterification and/or trans-esterification reaction ;
- (b) heating the resulting alkyl ester product with an excess of urea in an alkanol to from 55-90 °C;
- (c) cooling the product of step (b) to 0 °C to precipitate urea fatty acid alkyl ester adduct, and thereafter separating off said adduct to leave a solution mainly containing M3-fatty acid esters and an unsaponifiable portion ;
- (d) separating from the solution remaining from step (c) the w3-fatty acid alkyl esters and the unsaponifiable portion, preferably by extracting with a solvent ;
- (e) removing any solvent from the mixture obtained in step (d) ; and
- (f) cooling the concentrate obtained in step (e) to crystallize out cholesterol and to precipitate out other undefined unsaponifiable compounds, thereby to leave a refined fish oil concentrate.
- A one special feature of this process is that fatty acid compounds are not separated prior to precipitation of the urea adduct, but instead precipitate from the same non-uniform mixture of components like they are found in the basic raw material.
- Another special feature is that the precipitation of the urea adduct takes place in an alkaline environment, and in such a way that the alkaline environment is created through applying the base only in catalytic quantities such as a catalytic agent for the trans-esterification of glycerides to methyl esters and not as a means of saponification of the fatty acids.
- A third special feature is that the esterification and/or trans-esterification takes place at room temperature.
- A result of esterification or trans-esterification at low temperature and in an environment with low alkalinity is that isomerization of the double bonds is avoided, which results in a more uniform product with no toxic effect. At the same time transconfigurations are avoided. The remaining solution is thereafter extracted by means of a non-polar solvent, for example hexane, whereby the w3-fatty acids as well as cholesterol will be found in the non-polar phase.
- Thereafter the non-polar phase is treated to remove the solvent, as by being subjected to evaporation of the solvent under moderate conditions, for instance by means of vacuum distillation. The remaining ω3-concentrate now contains all the cholesterol, and it becomes apparent that the cholesterol does not dissolve easily in this concentrate and will crystallize on cooling. The M3- concentrate which is left will contain 20-30 per cent EPA by weight and 35-50 % DHA by weight. The remainder of the concentrate consists mainly of non-essential fatty acid compounds which are not important for our purpose.
- For a better understanding of the invention, we refer to the block diagram in Fig. 1 which shows diagrammatically one way of carrying out the invention and where each block represents a step in the process and is marked with a reference number. The flow. of the material to and from each block and between the blocks is marked by solid and dotted lines. In addition, each material is characterized by a letter.
- The basic material is fat and/or fatty acids from fish and especially fat and/or fatty acids obtained from the fish processing industry in connection with ensilage and or auto-catalysis processes, but the process may also be used with other forms of marine fat. This fatty raw material is called fish oil product in the claims.
- Such fat/fatty acids have a high content of saturated, unsaturated and polyunsaturated fatty acids with a chain length C 18, C 20 and C 22 as well as a certain amount of cholesterol, vitamins and other fat soluble products which are undefin- able, usually characterized as unsaponifiable, as well as fatty acid compounds with shorter chain lengths.
- Fat/fatty acids (A) from fish with a content of i. a. cholesterol, also called the fish oil product, is placed in a container for trans-esterification with an alcohol with a low boiling point (B), for instance methanol or ethanol, preferably methanol, and a catalytic agent as well as auxiliary compounds (C) to obtain a faster esterification and trans-esterification in order to prevent oxidization and dis-coloration. Potassium hydroxide may be used as a catalytic agent, and in order to prevent oxidization, especially when heavy metals such as chromium, iron, cobalt, nickel and copper are present, small amounts of the sodium salt of ethylenediaminetetra-acetic acid (EDTA-Na3) may be added. The esterification and trans-esterification take place under moderate conditions and stirring at about 20 °C for some hours. The formation of alkyl esters is nearly complete when the ester product has changed its appearance from opalescent to clear. The clear solution (D1) therefore contains alkyl esters of the fatty acids, glycerol, alkanol, as well as some water from the esterification of the free fatty acids.
- The clear solution is then heated to a temperature of 55-90°, preferably 60-80°, most preferably 65-68 °C, whereafter a fixed amount of urea (E) and alkanol (B) is added and stirred in until everything is completely dissolved. The amount of urea depends on the composition of the fatty acids so that if the raw material (A) contains 6-8 % EPA by weight, urea is added in the
ratio 3 parts urea by weight to 1 part alkyl ester. In order to ensure that the components are completely soluble, 9 parts alkanol by weight is added. - When everything is dissolved, the solution is slowly cooled to approx. 20 °C. An adduct of urea fatty ester (F) is crystallized and then removed by means of for instance decanting and filtration, whereafter the filter mass is cooled to 0 °C in order to crystallize a larger portion of the adduct (F). The adduct is then separated by a known method so that the remaining filter mass (G) contains the essential fatty acid fractions and the unsaponifiable fractions.
- The slightly alkaline filter mass (G) is saturated with hexane or other non-polar solvent, preferably hexane, and is extracted by means of this solvent through a known technique, as, for instance, by a continuing fluid-to-fluid counter current process, whereafter a further quantity of adduct of urea fatty ester may be crystallized. By means of this extraction two fluids are formed, consisting of hexane (I) and a residue (K).
- The hexane extract (1), which contains the alkyl- fatty esters of the polyunsaturated fatty acids 18 : 4003,20: 5ω3-and22 : 6 003 as well as cholesterol as the most important components, is washed in dilute hydrochloric acid (L) in order to neutralize possible potassium soaps of the essential polyunsaturated fatty acids in the hexane extract. The washing water is decanted.
- Hexane (H) is thereafter removed by evaporation of the extract (1) so that a concentrate is produced which is free from solvents (N) and which contains the compounds that are essential for the invention, the fatty acid compounds EPA and DHA as well as cholesterol.
- The dehydrated extract normally contains 20-30 % EPA, 35-45 % DHA, 10-20 % other polyunsaturated fatty acids, as well as 5-15 % cholesterol and undefined compounds, all by weight, but the exact composition referred to will depend on the type of fish used, the time of year the fish is caught, and the type and condition of the raw material.
- The concentrate of alkyl fatty acid ester (N) is thereafter cooled to approx. minus 25 °C, whereafter cholesterol (O) is crystallized. This is centrifuged and/or filtered.
- Further impurities which are present in the concentrate (N) may be removed by cooling the mixture to a temperature of lower than minus 25 °C, whereafter certain undefined compounds are precipitated and filtered by means of a known method. The remaining w3-concentrate (P) thus contains 20-35% EPA, 35-50 % DHA and 15-25 % of other polyunsaturated w3-fatty acid compounds (all by weight) as well as unsaturated fatty acid compounds which are not essential for the invention.
- Product .(p) which contains the alkyl esters of the corresponding w3-fatty acids may be utilized as it is or if desired the concentration of EPA and DHA may be increased.
- Since the product contains only small amounts of other fatty acids with the same chain length as EPA and DHA, it is well suited for separation of the essential fatty acids, EPA and DHA, by means of supercritical fluid extraction.
- Another method for increasing the concentration is by means of preparative liquid chromatography by which method a more than 90 % purity of the essential fatty acids is obtained.
- The alkaline residue (K) is acidified by means of concentrated hydrochloric acid (L) to a pH = 2, whereafter a hexane fraction (R) is precipitated in an upper layer which is separated. One may also subject the acid solution (S) to further extraction by means of hexane if this should be necessary, whereafter the hexane extracts are gathered. The hexane fractions (R) contain free fatty acids as well as some of their alkyl esters and fairly high percentages of EPA and DHA, but also a fairly substantial portion of C 18-, C 20- and C 22-fatty acids with lower unsaturation. This acid solution contains water, alcohol, alkanol, glycerol, urea and other products which may be retrieved by a separate process which is not described here.
- The fatty acid components of the hexane fraction are increased by evaporating hexane (H) in a separate piece of equipment.
- The remaining solution is esterified using lower alkanols, for instance methanol or ethanol by means of an appropriate catalytic agent (V) which for instance may be dehydrated hydrochloric acid, acetic acid chloride or boron-trichloride.
- The resultant alkyl ester (D2) from the fatty acid components (T) from
box 7 may be processed in various ways, for instance returned tobox 2 for urea precipitation of the less unsaturated fatty acids. - To 50 kg fish oil product (A) from cod entrails (containing 8 % EPA, 11 % DHA, and 2.3 % cholesterol all by weight) 400 I methanol (B) and 10 g EDTA Na3 (C) were added in a reactor. Potassium hydroxide (C) dissolved in methanol was added for neutralisation of free fatty acids in a quantity corresponding to a colour reaction of pH 12 on a moist pH-paper. Thereafter 50 I methanol (B) were added.
- The whole mixture was subjected to stirring for 15 hours at 20 °C in order to bring about a trans-esterification of the glycerides to methyl esters and esterification of the free fatty acids to methyl esters.
- When the trans-esterification was complete, the temperature was increased to 65-68 °C and 140 kg urea (E), as well as a fixed amount of methanol (B) were stirred in while being heated until everything seemed to be dissolved. Then the solution was slowly cooled to room temperature (approx. 20 °C), whereafter a urea adduct of fatty acid was precipitated (F). It contained the major portion of the saturated and lower unsaturated fatty acid methyl esters.
- The urea adduct was separated from the solution by decanting and filtering according to an ordinary, known technique. Result : 100.1 kg urea adduct (F).
- Thereafter the solution was cooled to 0-4 °C, whereby an additional 5.1 kg urea adduct (F) could be filtrated from the solution.
- This filtrate (G) contained 003-polyunsaturated fatty acid methyl esters, cholesterol and a residue of unwanted fatty acid fractions with lower unsaturated C 18, C 20 and C 22 fatty acid methyl esters. To this filtrate we added hexane for saturation, whereby a further amount of urea adduct (22 kg) could be separated. This hexane-saturated solution was extracted in a counter-current with hexane so that the hexane extract (1) finally made up approx. 300 I. The remaining unextracted solution is called (K). The hexane extract was thereafter evaporated. The yield of 003-fatty acid methyl ester concentrate : 10.2 kilos.
- The concentrate (N) which contained 23 % EPA, 41 % DHA and 8 % cholesterol, all by weight, was thereafter cooled to minus 25 °C, whereby pure cholesterol (O) crystallized and was removed by means of centrifuging during which time the residue in the centrifuge was washed with hexane with a lower temperature in order to remove the fatty acid methyl esters from the cholesterol crystals. Yield : 760 g pure cholesterol. The concentrated filtrate (P) contained 25 % EPA-methy. lester, 43 % DHA-methylester by weight based on the fatty acid portion, and traces of cholesterol.
- The above-mentioned extracted residue (K) was cleansed with a solution of concentrated hydrochloric acid, whereby one hexane phase could be filtered of f. Additional hexane was added to the batch, stirred and then precipitated. The hexane fractions were put together and the hexane evaporated. To 7.7 kilos of the remaining fatty acid and the methyl fatty acid fraction, 15
liter 2 % methanolic solution of boron trichloride were added. - Yield : 6 kilos methyl fatty acid esters, containing 13 % EPA-methylester, 17 % DHA-methylester and approximately 2 % cholesterol, all by weight.
- The methyl fatty acid concentrate, containing methanol, was returned to the process for treatment with urea.
- With this invention it has been possible to produce a very pure w3-concentrate of fatty acid alkyle esters, where the essential anti-thrombotic fatty acid components eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are present in a high concentration.
- Further, by means of the procedure invented, it has been possible in a simple manner to separate very pure and crystalline cholesterol. An additional product is a urea adduct of fatty acid components, but this is not of current interest.
- Another advantage with the invention is that it is possible to produce a urea adduct without following the cumbersome procedure of first producing the fatty acids, esterify these with alkanol and then separating them by means of the fractionated urea precipitation.
- By following the procedure invented, it is also possible to avoid the formation of emulsions in the phases, and the phase separation is thereby facilitated during later extraction stages.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT86906964T ATE49774T1 (en) | 1985-12-19 | 1986-11-21 | A PROCESS FOR THE PRODUCTION OF REFINED FISH OIL CONCENTRATE. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO855147 | 1985-12-19 | ||
NO855147A NO157302C (en) | 1985-12-19 | 1985-12-19 | PROCEDURE FOR THE PREPARATION OF A FISH OIL CONCENTRATE. |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0255824A1 EP0255824A1 (en) | 1988-02-17 |
EP0255824B1 true EP0255824B1 (en) | 1990-01-24 |
Family
ID=19888637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86906964A Expired - Lifetime EP0255824B1 (en) | 1985-12-19 | 1986-11-21 | A process for the production of refined fish oil concentrate |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0255824B1 (en) |
AR (1) | AR242111A1 (en) |
AU (1) | AU6621186A (en) |
CA (1) | CA1303416C (en) |
DD (1) | DD261805A1 (en) |
DE (1) | DE3668467D1 (en) |
IE (1) | IE59171B1 (en) |
IS (1) | IS1425B6 (en) |
MA (1) | MA20840A1 (en) |
MX (1) | MX168698B (en) |
NO (1) | NO157302C (en) |
NZ (1) | NZ218500A (en) |
PT (1) | PT83991B (en) |
WO (1) | WO1987003899A1 (en) |
ZA (1) | ZA868927B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678930B2 (en) | 2002-07-11 | 2010-03-16 | Pronova Biopharma Norge As | Process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
US7718698B2 (en) | 2002-07-11 | 2010-05-18 | Pronova Biopharma Norge As | Process for decreasing environmental pollutants in an oil or a fat |
US9234157B2 (en) | 2011-07-06 | 2016-01-12 | Basf Pharma Callanish Limited | SMB process |
US9260677B2 (en) | 2011-07-06 | 2016-02-16 | Basf Pharma Callanish Limited | SMB process |
WO2016028235A1 (en) * | 2014-08-18 | 2016-02-25 | Chiang Mai University | A system and method for extracting and/or concentrating vitamin e |
US9315762B2 (en) | 2011-07-06 | 2016-04-19 | Basf Pharma Callanish Limited | SMB process for producing highly pure EPA from fish oil |
US9370730B2 (en) | 2011-07-06 | 2016-06-21 | Basf Pharma Callanish Limited | SMB process |
EP3789476A1 (en) | 2015-05-13 | 2021-03-10 | Epax Norway AS | Very long chain polyunsaturated fatty acids from natural oils |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
DE69005459T2 (en) * | 1990-03-12 | 1994-04-14 | Einar Sola | METHOD OF FATIGUATION OF FATS IN POLYUNSATURATED FATTY ACIDS AND PHOSPHOLIPIDES AND USE OF THESE ENRICHED FATS. |
SE9303446D0 (en) * | 1993-10-20 | 1993-10-20 | Trikonex Ab | A novel urea fractionation process |
GB9404483D0 (en) * | 1994-03-08 | 1994-04-20 | Norsk Hydro As | Refining marine oil compositions |
TW425285B (en) | 1996-06-10 | 2001-03-11 | Viva America Marketing Inc | Fish oil and garlic nutritive supplement |
US6313167B1 (en) | 1997-06-16 | 2001-11-06 | Nippon Suisan Kaisha Ltd. | Composition having capability of removing risk factor during exercise |
NO309795B1 (en) * | 1998-07-01 | 2001-04-02 | Norsk Hydro As | Method for stabilizing oils and their use, method for stabilizing pigments, and method for preparing for |
IT1308613B1 (en) | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS. |
NO311041B1 (en) * | 1999-12-22 | 2001-10-01 | Norsk Hydro As | Stabilization of pigments and polyunsaturated oils and oil concentrates |
AU2001232786A1 (en) | 2000-01-11 | 2001-07-24 | Monsanto Company | Process for making an enriched mixture of polyunsaturated fatty acid esters |
AT414205B (en) | 2000-06-20 | 2006-10-15 | Vis Vitalis Lizenz & Handels | PROCESS FOR PRODUCING UNSATURATED FATTY ACID DRY CONCENTRATE |
ITMI20010129A1 (en) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE |
ITMI20032247A1 (en) | 2003-11-19 | 2005-05-20 | Tiberio Bruzzese | INTERACTION OF POLAR DERIVATIVES OF COMPOUNDS INSATURATED WITH INORGANIC SUBSTRATES |
DK3467096T3 (en) | 2005-06-07 | 2022-03-28 | Dsm Nutritional Products Ag | EUKARYOTE MICRO-ORGANISMS FOR THE PRODUCTION OF LIPIDS AND ANTIOXIDANTS |
ITMI20051560A1 (en) * | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS |
MX2009001346A (en) | 2006-08-01 | 2009-04-17 | Ocean Nutrition Canada Ltd | Oil producing microbes and methods of modification thereof. |
EP3865469A3 (en) | 2009-12-30 | 2021-11-17 | BASF Pharma (Callanish) Limited | Polyunsaturated fatty acid compositions obtainable by a simulated moving bed chromatographic separation process |
ITMI20102297A1 (en) | 2010-12-15 | 2012-06-16 | Prime Europ Therapeuticals | PROCEDURE FOR STABILIZING FAT POLYINSATURED ACIDS BY MEANS OF METAL HYDRATES |
EP2673254B1 (en) * | 2011-03-08 | 2017-12-27 | Cognis IP Management GmbH | A process for the distillation of fatty acid esters |
GB201111594D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New improved process |
GB201300354D0 (en) | 2013-01-09 | 2013-02-20 | Basf Pharma Callanish Ltd | Multi-step separation process |
EP2970926B1 (en) | 2013-03-13 | 2018-01-31 | DSM Nutritional Products AG | Engineering microorganisms |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
EP3118186B1 (en) | 2013-12-11 | 2022-02-09 | Novasep Process | Chromatographic facility for producing polyunsaturated fatty acids |
WO2015104464A1 (en) | 2014-01-07 | 2015-07-16 | Novasep Process | Process for purifying aromatic amino acids |
US9163198B2 (en) * | 2014-01-17 | 2015-10-20 | Orochem Technologies, Inc. | Process for purification of EPA (eicosapentanoic acid) ethyl ester from fish oil |
AR104042A1 (en) | 2015-03-26 | 2017-06-21 | Mara Renewables Corp | HIGH-DENSITY PRODUCTION OF BIOMASS AND OIL USING GLUCEROL IN GROSS |
US10821090B2 (en) | 2015-03-26 | 2020-11-03 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
AU2016293487B2 (en) | 2015-07-13 | 2021-07-01 | MARA Renewables Corporation | Enhancing microalgal metabolism of xylose |
US10851395B2 (en) | 2016-06-10 | 2020-12-01 | MARA Renewables Corporation | Method of making lipids with improved cold flow properties |
JP7177081B2 (en) | 2017-09-14 | 2022-11-22 | ファーメンタ バイオテク リミテッド | Improved method of extracting cholesterol from fish oil waste residue |
US10196586B1 (en) * | 2018-02-14 | 2019-02-05 | Golden Omega S.A. | Feed ingredient |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1176916B (en) * | 1984-10-10 | 1987-08-18 | Elvira Pistolesi | PHARMACEUTICAL OR DIETETIC COMPOSITION WITH HIGH ANTI-THROMBOTIC AND ANTI-ARTERIOSCLEROTIC ACTIVITY |
-
1985
- 1985-12-19 NO NO855147A patent/NO157302C/en not_active IP Right Cessation
-
1986
- 1986-11-21 AU AU66211/86A patent/AU6621186A/en not_active Withdrawn
- 1986-11-21 IE IE306486A patent/IE59171B1/en not_active IP Right Cessation
- 1986-11-21 WO PCT/NO1986/000077 patent/WO1987003899A1/en active IP Right Grant
- 1986-11-21 DE DE8686906964T patent/DE3668467D1/en not_active Expired - Lifetime
- 1986-11-21 IS IS3159A patent/IS1425B6/en unknown
- 1986-11-21 EP EP86906964A patent/EP0255824B1/en not_active Expired - Lifetime
- 1986-11-25 ZA ZA868927A patent/ZA868927B/en unknown
- 1986-11-27 CA CA000523914A patent/CA1303416C/en not_active Expired - Lifetime
- 1986-12-03 NZ NZ218500A patent/NZ218500A/en unknown
- 1986-12-08 MX MX004578A patent/MX168698B/en unknown
- 1986-12-17 DD DD86297792A patent/DD261805A1/en not_active IP Right Cessation
- 1986-12-19 PT PT83991A patent/PT83991B/en not_active IP Right Cessation
- 1986-12-19 AR AR86306258A patent/AR242111A1/en active
- 1986-12-19 MA MA21072A patent/MA20840A1/en unknown
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678930B2 (en) | 2002-07-11 | 2010-03-16 | Pronova Biopharma Norge As | Process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
US7718698B2 (en) | 2002-07-11 | 2010-05-18 | Pronova Biopharma Norge As | Process for decreasing environmental pollutants in an oil or a fat |
US7732488B2 (en) | 2002-07-11 | 2010-06-08 | Pronova Biopharma Norge As | Pharmaceutical composition comprising low concentrations of environmental pollutants |
US9234157B2 (en) | 2011-07-06 | 2016-01-12 | Basf Pharma Callanish Limited | SMB process |
US9260677B2 (en) | 2011-07-06 | 2016-02-16 | Basf Pharma Callanish Limited | SMB process |
US9315762B2 (en) | 2011-07-06 | 2016-04-19 | Basf Pharma Callanish Limited | SMB process for producing highly pure EPA from fish oil |
US9370730B2 (en) | 2011-07-06 | 2016-06-21 | Basf Pharma Callanish Limited | SMB process |
WO2016028235A1 (en) * | 2014-08-18 | 2016-02-25 | Chiang Mai University | A system and method for extracting and/or concentrating vitamin e |
EP3789476A1 (en) | 2015-05-13 | 2021-03-10 | Epax Norway AS | Very long chain polyunsaturated fatty acids from natural oils |
Also Published As
Publication number | Publication date |
---|---|
AR242111A1 (en) | 1993-03-31 |
CA1303416C (en) | 1992-06-16 |
NO855147L (en) | 1987-06-22 |
MA20840A1 (en) | 1987-07-01 |
NZ218500A (en) | 1989-03-29 |
ZA868927B (en) | 1987-08-26 |
AU6621186A (en) | 1987-07-15 |
DE3668467D1 (en) | 1990-03-01 |
NO157302B (en) | 1987-11-16 |
WO1987003899A1 (en) | 1987-07-02 |
IE59171B1 (en) | 1994-01-12 |
IS3159A7 (en) | 1987-06-20 |
EP0255824A1 (en) | 1988-02-17 |
IS1425B6 (en) | 1990-03-28 |
IE863064L (en) | 1987-06-19 |
NO157302C (en) | 1988-02-24 |
PT83991A (en) | 1987-01-01 |
MX168698B (en) | 1993-06-04 |
DD261805A1 (en) | 1988-11-09 |
PT83991B (en) | 1989-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0255824B1 (en) | A process for the production of refined fish oil concentrate | |
DE60032337T2 (en) | LIPASE CATALYSED GREASING OF FISH OILS | |
EP3294850B1 (en) | Very long chain polyunsaturated fatty acids from natural oils | |
CA2822314C (en) | Concentrate of omega 3 | |
EP0178442A1 (en) | Process for the selective enrichment of a delta-6 and delta-9 fatty acids containing mixture with delta-6 polyunsaturated fatty acids, the enriched fractions thus obtained and their use | |
JPS63162796A (en) | Fractionation of fatty acid | |
JPH0159318B2 (en) | ||
AU670723B2 (en) | A process for separating lipophilic compounds | |
US5849940A (en) | Triglyceride fractionation | |
US2553288A (en) | Solvent treatment | |
EP0406945B1 (en) | Process for soap splitting using a high temperature treatment | |
US3345389A (en) | Separation of fatty materials | |
US2682550A (en) | Solvent treatment | |
JP3656863B2 (en) | Process for producing fats and oils having a high content of highly unsaturated fatty acid residues | |
WO1993019144A1 (en) | Fatty acid esters | |
JPH0649480A (en) | Separation of unsaturated compound | |
EP4289281A1 (en) | A method of efficiently separating solid fat from polyunsaturated fatty acid grease | |
JP3461378B2 (en) | Purification method of eicosapentaenoic acid or its ester | |
JPH035496A (en) | Production of cholesterol | |
JPH02214798A (en) | Method for deacidification | |
EP4289280A1 (en) | A method of efficiently separating solid fat from polyunsaturated fatty acid grease | |
CN117043308A (en) | Method for obtaining cholesterol present in fish oil | |
JPH04100898A (en) | Fractionation of eicosatetraenoic acid and alcohol ester thereof | |
JPS62247000A (en) | Treatment of soap waste liquid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19870904 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19880719 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 49774 Country of ref document: AT Date of ref document: 19900215 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3668467 Country of ref document: DE Date of ref document: 19900301 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 86906964.1 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19951113 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19951116 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19951129 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19951208 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19960101 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19960109 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19961121 Ref country code: AT Effective date: 19961121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19961122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19961130 Ref country code: CH Effective date: 19961130 Ref country code: BE Effective date: 19961130 |
|
BERE | Be: lapsed |
Owner name: NORSK HYDRO A/S Effective date: 19961130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19970601 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19970601 |
|
EUG | Se: european patent has lapsed |
Ref document number: 86906964.1 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20031110 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20031119 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20031204 Year of fee payment: 18 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050601 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20041121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050729 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051121 |